Locations:
SearchLearn about featured cancer clinical trials currently enrolling, or search our cancer clinical trials database for all open and accruing studies
Breast
Phase III study evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy
GBG 1115 | 15-1373
View full trial information.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Esophageal
A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel
HCP 2215 | 031520C
View full trial information.
Pancreas
A Phase II Study of Second-Line Therapy with Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
CASE 5214 | 15-166
View full trial information.
Renal
A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab (Msb0010718c) In Combination With Axitinib (Inlyta®) Versus Sunitinib (Sutent®) Monotherapy In The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma
PFIZ 2816 | 16-573
View full trial information.
Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults with Advanced Solid Tumors
GITR 1Y15 | 101506C
View full trial information.
Myelodysplastic Syndrome (MDS)
A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo For the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions
CLGN 2915 | 16-462
View full trial information.
Lymphoma, Diffuse Large B Cell
A Phase I/II Study of Carfilzomib in Combination with R-CHOP (CR-CHOP) for Patients with Diffuse Large B -Cell Lymphoma
CASE 3413 | 14-256
View full trial information.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients